A randomized phase I study comparing the multi-targeted inhibitor dovitinib (VEGFR, PDGFR, FGFR) versus sorafenib (VEGFR, PDGFR) in advanced HCC demonstrated comparable median overall survival and time to progression, with subgroup analysis suggesting improved survival for dovitinib-treated patients with baseline sVEGFR1 or HGF below median levels; however, no superiority over sorafenib was observed, and no phase 3 trial is planned (73). The gene discussed is HGF; the disease is hepatocellular carcinoma.